SG Americas Securities LLC Has $57,000 Stake in Nektar Therapeutics (NASDAQ:NKTR)

SG Americas Securities LLC lifted its holdings in Nektar Therapeutics (NASDAQ:NKTR) by 30.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 101,687 shares of the biopharmaceutical company’s stock after acquiring an additional 23,829 shares during the quarter. SG Americas Securities LLC owned approximately 0.05% of Nektar Therapeutics worth $57,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the business. Metropolitan Life Insurance Co NY grew its holdings in Nektar Therapeutics by 43.7% during the 4th quarter. Metropolitan Life Insurance Co NY now owns 11,340 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 3,450 shares during the last quarter. Syntax Advisors LLC acquired a new position in shares of Nektar Therapeutics during the fourth quarter worth approximately $27,000. Financial Advocates Investment Management bought a new stake in shares of Nektar Therapeutics during the fourth quarter valued at approximately $28,000. UBS Group AG grew its stake in shares of Nektar Therapeutics by 396.1% during the third quarter. UBS Group AG now owns 48,897 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 39,041 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its holdings in shares of Nektar Therapeutics by 280.5% in the first quarter. Tower Research Capital LLC TRC now owns 41,048 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 30,261 shares in the last quarter. 75.88% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on NKTR shares. William Blair reiterated a “market perform” rating on shares of Nektar Therapeutics in a research report on Tuesday, March 5th. Jefferies Financial Group raised their price target on Nektar Therapeutics from $0.50 to $1.00 and gave the company a “hold” rating in a report on Wednesday, March 6th. Finally, StockNews.com started coverage on Nektar Therapeutics in a report on Friday, January 26th. They set a “hold” rating for the company. One analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the company. According to MarketBeat.com, Nektar Therapeutics has a consensus rating of “Hold” and a consensus price target of $3.50.

Nektar Therapeutics Stock Performance

Shares of Nektar Therapeutics stock opened at $1.24 on Monday. Nektar Therapeutics has a 52 week low of $0.41 and a 52 week high of $1.75. The stock has a market capitalization of $227.69 million, a price-to-earnings ratio of -0.85 and a beta of 0.90. The firm has a fifty day moving average of $0.96 and a two-hundred day moving average of $0.68.

Nektar Therapeutics (NASDAQ:NKTR) last released its earnings results on Monday, March 4th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.01). The company had revenue of $23.89 million during the quarter, compared to analyst estimates of $17.09 million. Nektar Therapeutics had a negative net margin of 306.31% and a negative return on equity of 96.80%. During the same period in the previous year, the company posted ($0.32) EPS. As a group, research analysts forecast that Nektar Therapeutics will post -0.93 EPS for the current fiscal year.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer.